UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000003670
Receipt No. R000004449
Scientific Title A Randomized Phase II/III Trial of Tri-weekly Intravenous versus Tri-weekly Intraperitoneal Carboplatin Both in Combination with Weekly Intravenous Paclitaxel for Newly Diagnosed Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Date of disclosure of the study information 2010/06/01
Last modified on 2020/12/04 11:30:39

No. Disposal Last modified on Item of update
1 Insert 2010/05/28 12:37:11
2 Update 2010/11/29 14:05:24 Email
3 Update 2010/12/28 10:17:53 Institutions
4 Update 2011/05/31 10:00:55 Institutions
5 Update 2011/11/30 08:29:15 Post marketing survey by drug manufacture etc., specified by Japanese law.
6 Update 2011/12/28 10:55:22 Key exclusion criteria
Key exclusion criteria
7 Update 2011/12/28 10:57:42 Anticipated trial start date
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
8 Update 2011/12/28 11:23:46 Division name
9 Update 2012/05/11 08:01:35 Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
10 Update 2012/05/28 11:15:43 Institutions
11 Update 2012/05/28 11:22:06 URL releasing protocol
12 Update 2012/12/28 10:18:10 Institutions
13 Update 2013/05/28 15:26:20 Target sample size
14 Update 2013/05/28 15:34:51 TEL
Organization
Organization
Division name
Division name
Address
Address
TEL
15 Update 2013/05/28 15:47:18 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
16 Update 2013/05/28 16:00:18 Division name
Division name
Institute
17 Update 2013/05/28 16:16:20 Organization
Organization
Division name
Division name
Address
18 Update 2013/05/28 16:28:04 Name of secondary funder(s)
19 Update 2013/11/28 14:59:44 Email
Email
20 Update 2014/01/08 12:26:18 Institutions
21 Update 2014/05/29 09:41:51 Institutions
22 Update 2015/05/28 12:20:37 Name of person sending information
Name of person sending information
23 Update 2015/05/28 12:28:57 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
24 Update 2015/07/03 17:59:41 Institutions
25 Update 2016/05/12 16:09:38 Region
26 Update 2016/05/12 16:28:42 Name of primary sponsor
Organization
Category of Funding Organization
27 Update 2016/05/12 16:30:53 Institutions
28 Update 2016/06/07 11:21:32 Email1
Institutions
29 Update 2016/08/17 11:05:29 Recruitment status
30 Update 2017/06/01 09:41:18 Organization
Organization
31 Update 2017/06/01 10:01:32 Randomization unit
Target sample size
32 Update 2017/12/04 11:22:13 Name of person sending information
Nationality of Funding Organization
Nationality of Funding Organization
Institutions
33 Update 2018/06/04 11:15:05 Institutions
34 Update 2018/09/27 12:33:18 Division name
Division name
35 Update 2018/10/09 10:20:40 Institutions
36 Update 2018/10/10 14:40:46 Name of person sending information
Name of person sending information
37 Update 2019/06/03 15:17:59 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address

Last name of contact person

Last name of contact person
Zip code
Address
Organization1
Address1
Tel1
Email1
Organization
Organization
Address
Address
Tel
Email
Secondary IDs
Study ID_1
Org. issuing International ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
Org. issuing International ID_2
38 Update 2019/06/03 15:18:44 Number of participants that the trial has enrolled
39 Update 2019/06/03 15:22:45 Date of IRB
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
40 Update 2019/06/05 11:11:07 Date of IRB
41 Update 2019/12/03 16:27:23 Institutions
42 Update 2019/12/04 11:37:41 Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
43 Update 2020/12/04 11:30:40 Date trial data considered complete


Contact us.